Glythera relocated to the Newcastle-upon- in 2012, following investment from IP Group and the Finance for Business North East Technology Fund which underpinned the commercialisation of its core, enabling technology platforms. Glythera is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well a broader based therapeutics. Our main goal i
s to develop effective therapies to improve patients’ lives. Our mission is to enables improved clinical regimes through creation of the next generation of safe, efficacious biotherapeutic products in the oncology and therapeutics markets. With substantial experience and expertise in bioprocessing and chemistry development, we have a proven track record of supporting programs centred on our core technologies - PermaLink™ and PermaCarb™
PermaLink™
Permalink™ is a linker chemistry platform that supports highly selective, cysteine targeted conjugation. Targeted addition and improved stability mean that PermaLink™ offers significant advantages over existing linker chemistries commonly associated with the development of Antibody Drug Conjugates (ADC). The PermaLink™ platform has also been used in the exemplification of PEGylated products and conjugate vaccines. PermaCarb™
PermaCarb™ technology is an enabling discovery platform which uses stable glycan analogues to improve product performance and biobetter development. PermaCarb™ has been demonstrated in a range of biotherapeutics and has a broad application in drug development including next generation biologics.
